These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14992909)

  • 1. New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron.
    Aylsworth CL; Stefan F; Woitas K; Rieger RH; LeBoutillier M; DiSesa VJ
    Ann Thorac Surg; 2004 Mar; 77(3):973-6. PubMed ID: 14992909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques.
    Carter AJ; Hicks K; Heldman AW; Resar JR; Laird JR; Coombs VJ; Brinker JA; Blumenthal RS
    Cathet Cardiovasc Diagn; 1996 Sep; 39(1):97-102. PubMed ID: 8874958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
    Mabry CD; Thompson BW; Read RC; Campbell GS
    Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining the standard: a quality assurance study for new equipment in the Michigan ECMO Program.
    Fleming GM; Gupta M; Cooley E; Remenapp R; Bartlett RH; Annich GM
    ASAIO J; 2007; 53(5):556-60. PubMed ID: 17885327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
    Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
    Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.
    Svenmarker S; Appelblad M; Jansson E; Häggmark S
    Perfusion; 2004; 19(5):289-94. PubMed ID: 15506033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hand-held personal digital assistant program for the HEMOCHRON RxDx heparin and protamine dosing system.
    El Rouby S; Rinehart K; Zucker ML; LaDuca FM
    J Extra Corpor Technol; 2003 Sep; 35(3):212-7. PubMed ID: 14653423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
    Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
    Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass.
    Welsby IJ; McDonnell E; El-Moalem H; Stafford-Smith M; Toffaletti JG
    J Clin Monit Comput; 2002 Jul; 17(5):287-92. PubMed ID: 12546261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability.
    Dirkmann D; Nagy E; Britten MW; Peters J
    BMC Anesthesiol; 2019 Sep; 19(1):174. PubMed ID: 31492108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated clotting time tests with heparinase in the management of pediatric patients on cardiopulmonary bypass.
    Kriesmer P; Payne NR; Tessmer J; Uden DL
    ASAIO J; 1993; 39(4):942-5. PubMed ID: 8123932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hemochron Response RxDx heparin and protamine dosing system.
    Jaryno SA; Zucker ML; LaDuca FM
    J Extra Corpor Technol; 2004 Sep; 36(3):258-62. PubMed ID: 15559745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer].
    Li J; Cong YL; Tu GH; Yang L; Zhu BB; Jin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1269-71. PubMed ID: 17686264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
    Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
    J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated clotting time for control of anticoagulation during surgery.
    Lefemine AA; Lewis M
    Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How does the age of a blood sample affect it's activated clotting time? Comparison of eight different devices.
    Searles B; Nasrallah F; Darling E; Yarcusko S
    J Extra Corpor Technol; 2002 Sep; 34(3):175-7. PubMed ID: 12395961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transition from Hemochron Response to Hemochron Signature Elite Activated Clotting Time Devices in a Congenital Cardiac Surgery Practice.
    Matte GS; Howe RJ; Ibla J; Emani S; Emani SM
    J Extra Corpor Technol; 2019 Dec; 51(4):221-226. PubMed ID: 31915405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintaining adequate anticoagulation on extracorporeal membrane oxygenation therapy: Hemochron Junior Low Range versus Hemochron 400.
    Colby CE; Sheehan A; Benitz W; Van Meurs K; Halamek LP; Moss RL
    J Extra Corpor Technol; 2003 Mar; 35(1):35-8. PubMed ID: 12680494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation.
    Chia S; Van Cott EM; Raffel OC; Jang IK
    Thromb Haemost; 2009 Mar; 101(3):535-40. PubMed ID: 19277416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.